Market capitalization | $406.08m |
Enterprise Value | $357.16m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.54 |
P/S ratio (TTM) P/S ratio | 6.30 |
P/B ratio (TTM) P/B ratio | 5.53 |
Revenue growth (TTM) Revenue growth | -12.86% |
Revenue (TTM) Revenue | $64.45m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Codexis, Inc. forecast:
8 Analysts have issued a Codexis, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 64 64 |
13%
13%
|
|
Gross Profit | 44 44 |
12%
12%
|
|
EBITDA | -43 -43 |
22%
22%
|
EBIT (Operating Income) EBIT | -51 -51 |
22%
22%
|
Net Profit | -62 -62 |
24%
24%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood City, CA.
Head office | United States |
CEO | Stephen Dilly |
Employees | 174 |
Founded | 2002 |
Website | www.codexis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.